CJC-1295 Buyer's Guide: 4 Decisions Before You Buy
The pituitary gland doesn't just release growth hormone in a steady stream. It fires in pulses, sharp bursts triggered by a signaling molecule called growth hormone releasing hormone, or GHRH, which is the chemical your hypothalamus sends down to tell the pituitary it's time to release. Between those pulses, a separate molecule called somatostatin acts like a brake, suppressing release so the system can reset. The whole rhythm depends on that push and pull, gas and brake, working in alternating cycles throughout the day and especially during deep sleep.
CJC-1295 is a synthetic version of GHRH, which means it works by mimicking that same signal to the pituitary rather than replacing the growth hormone itself. That distinction matters more than most people realize when they're deciding what to buy.
The first decision is whether to buy CJC-1295 with DAC or without it.
DAC stands for drug affinity complex, which is a chemical modification that allows the peptide to bind to albumin proteins circulating in your blood and use them as a kind of slow-release reservoir. This extends the half-life from roughly 30 minutes up to about seven days, so instead of injecting daily you're only injecting once or twice a week. That sounds convenient, and it is. The problem is what that convenience costs you.
When you take CJC-1295 with DAC, you're not creating pulses of GHRH. You're creating a flat, sustained elevation of GHRH signaling that lasts all week. The pituitary is designed to respond to sharp peaks of GHRH, not a continuous low-level hum of it, and chronic overstimulation of any receptor system tends to produce the same result: the receptors become less responsive over time. More importantly, the entire reason to use a secretagogue rather than injecting growth hormone directly is to preserve the pulsatile pattern your body's own feedback systems depend on. If you want flat growth hormone elevation, exogenous growth hormone does that job better and comes with decades of clinical data behind it. No DAC is the only version worth buying if the goal is to work with your physiology rather than override it.
The second decision is whether to buy CJC-1295 by itself or in a blend with Ipamorelin.
CJC-1295 without DAC works at the GHRH receptor, telling the pituitary to release. Ipamorelin works at a completely different receptor called GHSR1a, which is the ghrelin receptor, and it amplifies the release signal from a second pathway. When you combine them, you get simultaneous stimulation through both channels at once, and the growth hormone pulse produced is substantially larger than either peptide would generate alone. The blend approach is common enough that many research suppliers sell them pre-mixed in a single vial, and if that's what you're buying, keeping the math clear matters. Five milligrams of CJC plus five milligrams of Ipamorelin in two milliliters of bacteriostatic water gives you 250 micrograms of each per 10 units on an insulin syringe, so both compounds are dosed equally at whatever volume you're drawing.
The third decision is how to cycle, and specifically why.
The common explanation is that you need to cycle CJC-1295 to prevent receptor desensitization, but that explanation is only half right. CJC-1295 works through GHRH receptors, and the evidence suggests those receptors are quite stable under continuous stimulation. Tesamorelin, which is another synthetic GHRH analog and works through the same receptor, was run continuously for 52 weeks in the FDA clinical trials that led to its approval, and IGF-1 levels didn't decline. They held at the same levels reached at week 26 all the way through week 52. That's a year of daily GHRH receptor stimulation with no meaningful attenuation.
Ipamorelin is a different story. The ghrelin receptor, GHSR1a, desensitizes through a process called beta-arrestin mediated internalization, which means the cells physically pull the receptors off the surface and reduce the number available to respond to the signal. The longer you stimulate those receptors without a break, the fewer of them are present to respond, and the weaker the signal becomes. After roughly 12 to 16 weeks of continuous use, IGF-1 levels can drop 20 to 30 percent from peak even without changing the dose at all. That's not a theoretical concern, that's the receptor biology playing out exactly as the mechanism predicts.
This is why the standard cycling recommendation of three months on, one month off exists. The month off allows the ghrelin receptors to upregulate back toward baseline so that when you restart, you're stimulating a fully responsive system again. The CJC side doesn't need that break. The cycle is driven entirely by the Ipamorelin.
The fourth decision is knowing when secretagogues are no longer the right tool.
Secretagogues work by optimizing what your own pituitary can produce, which means they're operating within your biological ceiling and they keep the body's feedback loop intact. Your hypothalamus, your pituitary, and your liver are all still in conversation with each other, adjusting the signal up or down based on what the system needs. When you inject exogenous growth hormone, you bypass that conversation entirely and push circulating growth hormone above whatever your feedback loop would normally allow.
The two approaches cannot run together effectively for a straightforward reason. After a single injection of exogenous growth hormone, the resulting elevation in IGF-1 and growth hormone itself triggers somatostatin release, and that somatostatin suppresses the GHRH pathway by 86 percent. The CJC you're using is trying to stimulate the pituitary through GHRH receptors, but the somatostatin has essentially locked that pathway down, so the peptide can't do its job. You're paying for a signal that's being blocked before it can act.
If your goals require more growth hormone than your pituitary can produce on its own, the answer is to drop the secretagogues entirely and move to exogenous growth hormone directly. Trying to stack them doesn't produce additive benefit, it produces interference.
Most people using secretagogues never need to make that fourth decision. The ceiling your own pituitary can reach, when stimulated optimally through both the GHRH and ghrelin pathways simultaneously, is meaningful and it arrives with none of the feedback suppression that exogenous growth hormone introduces. The case for secretagogues was never that they're as powerful as growth hormone. It's that they work with the system instead of around it, and for most people at most stages, that's exactly what they need.
References
- FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
- Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
- PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
- Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.